Treace Medical Concepts, Inc. (TMCI)
| Market Cap | 123.10M |
| Revenue (ttm) | 212.69M |
| Net Income (ttm) | -59.00M |
| Shares Out | 64.62M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 288,380 |
| Open | 1.890 |
| Previous Close | 1.920 |
| Day's Range | 1.870 - 1.955 |
| 52-Week Range | 1.170 - 7.780 |
| Beta | 0.88 |
| Analysts | Hold |
| Price Target | 4.77 (+150.39%) |
| Earnings Date | May 8, 2026 |
About TMCI
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percupla... [Read more]
Financial Performance
In 2025, Treace Medical Concepts's revenue was $212.69 million, an increase of 1.59% compared to the previous year's $209.36 million. Losses were -$59.00 million, 5.85% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for TMCI stock is "Hold." The 12-month stock price target is $4.77, which is an increase of 150.39% from the latest price.
News
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgic...
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
New portfolio addition taps into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition tap...
Treace Medical Concepts Earnings Call Transcript: Q4 2025
Revenue declined 9% in Q4 2025 due to product mix, but case volumes and adjusted EBITDA improved. 2026 guidance anticipates flat to -6% revenue, with growth expected in Q4 from new product launches and continued cost reductions.
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical Concepts Transcript: 44th Annual J.P. Morgan Healthcare Conference
Expanded to a comprehensive 3D bunion solutions portfolio, driving strong surgeon adoption and mid-single-digit procedure growth in late 2025. New MIS and fixation products are broadening market reach, while high gross margins and improved profitability position the company for continued growth in 2026.
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical Secures Up to $175 Million in Debt Financing
New 5-Year Agreement Provides Continued Financial Strength & Flexibility New 5-Year Agreement Provides Continued Financial Strength & Flexibility
Treace Medical Concepts Transcript: UBS Global Healthcare Conference 2025
A broadened product portfolio now addresses all major bunion categories, driving increased surgeon adoption and procedure volume growth, though revenue is tempered by a shift to lower ASP products. Strong gross margins, reduced cash burn, and new AI-driven technologies position the company for future growth and deeper market penetration.
Treace Announces Participation in Two Upcoming Investor Conferences
PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical Concepts Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 11% year-over-year to $50.2 million, but softness in Lapiplasty volumes and macroeconomic headwinds led to a revised full-year outlook of 1–2% revenue growth. New product launches drove case volume growth, though at lower ASPs, and cost controls improved Adjusted EBITDA loss by 49% in Q3.
Treace to Report Third Quarter 2025 Financial Results on November 6, 2025
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2025 American Orthopaedic Foot & Ankle Society Annual Meeting
PONTE VERDE, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgic...
Treace Medical Concepts Transcript: Investor Day 2025
A comprehensive portfolio of new minimally invasive and instrumented bunion correction systems is being launched, targeting significant market expansion and aiming to double business by increasing penetration. Key growth drivers include innovation in core procedures, digital solutions, and expansion into adjacent foot pathologies.
Treace Medical Concepts Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 7% year-over-year to $47.4 million, with improved margins and reduced losses. Expanded product launches and strong surgeon engagement support confidence in accelerating growth for the remainder of 2025, with full-year revenue guidance reaffirmed at $224–$230 million.
Treace Medical Concepts Reports Second Quarter 2025 Financial Results
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
Notice to Long-Term Shareholders of Maison Solutions Inc. (NASDAQ: MSS); Napco Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NYSE: VIRT): Grabar Law Office is Investigating Claims on Yo
PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Maison Solutions Inc. (NASDAQ: MSS) Class Action Survives Motion to Dismiss:
TMCI Investors Have Opportunity to Join Treace Medical Concepts, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concep...
Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology
PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgica...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Treace Medical To Contact Him Directly To Discuss Their Options
Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsu...
Treace Medical Concepts Earnings Call Transcript: Q1 2025
Q1 2025 revenue grew 3% year-over-year to $52.6M, with improved margins and reduced losses. New bunion systems and technologies are set to drive accelerated growth in the second half, supporting reaffirmed 2025 guidance of $224–$230M and a break-even adjusted EBITDA target.